Oral antidiabetic treatment and bone impairment

Filled Under: ATTI - XVI CONGRESSO NAZIONALE SIOMMMS 2016

Year: 2016

Number: 3/4

Author:

Oral antidiabetic treatment and bone impairment

Osteoporosis is a progressive skeletal disorder that is characterized by compromised bone strength and increased risk of fracture. Type 2 diabetes is associated with impaired bone strength, although it is characterized by normal or elevated bone mineral density. Besides a higher falls frequency the lower quality of diabetics bone plays the crucial role in this case. Several therapeutic strategies are available to achieve the best outcomes in the management of diabetes mellitus but these have different effects on bone metabolism. Therefore, one of the factors affecting their fracture risk is a choice of antidiabetic treatment. So far, professional societies have warned before the thiazolidinediones use only, but gliflozines can be harmful for bone too. Metformin, sulfonylureas, GLP-1 agonists and DPP-4 inhibitors belong to the drugs without a clear negative effect on the fracture risk.